Dr Chari on Findings From the MonumenTAL-1 Trial in Relapsed/Refractory Multiple Myeloma

Ajai Chari, MD, discusses the efficacy of treating patients with less frequent or lower intensity dosing of talquetamab in patients with relapsed/refractory multiple myeloma, as evaluated in the phase 1/2 MonumenTAL-1 study.

Related Keywords

California ,United States ,San Francisco , ,Myeloma Program ,University Of California ,Helen Diller Family Comprehensive Cancer Center ,Findings From ,Refractory Multiple ,Multiple Myeloma Program ,Diller Family Comprehensive Cancer Center ,Ash Annual Meeting And Exposition ,Onclive Tv ,Multiple Myeloma ,